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Abstract
Background:  Fusarium  spp. is being isolated with increasing frequency as a pathogen in
oncohematologic patients. Caspofungin and amphotericin B have been reported to have synergistic
activity against Fusarium spp.
Case presentation: We herein report a case of disseminated fusariosis diagnosed by chest CT
scan and positive blood cultures to Fusarium  spp. Because the patient's clinical condition
deteriorated, CRP levels increased, and blood cultures continued to yield Fusarium spp. despite
liposomal amphotericin B monotherapy up to 5 mg/kg daily, treatment with caspofungin was added.
Within 2 weeks of onset of combined antifungal therapy, the chest CT scan demonstrated a
progressive resolution of the pulmonary lesions. Upon discontinuation of intravenous antifungals,
the patient received suppressive therapy with oral voriconazole. Three months later, a chest CT
scan showed no abnormalities. Twenty-five months after discontinuation of all antifungal therapy,
the patient remains in complete remission of her neoplastic disease with no signs of clinical activity
of the Fusarium infection.
Conclusion: This is the first description of successful treatment of disseminated fusariosis in a
pediatric patient with acute lymphoblastic leukemia with caspofungin and amphotericin B followed
by oral suppressive therapy with voriconazole.
Background
Fusarium spp. is a saprophytic mould that is ubiquitous in
the soil. Invasive fusariosis may follow the inhalation of
airborne conidia or the inoculation of conidia through a
skin breach associated with indwelling catheters, wounds,
burns, or onychomycosis. Deep-seated and disseminated
infections caused by Fusarium spp. are being diagnosed
with increasing frequency in patients with hematological
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malignancies [1]. The Fusarium species most frequently
involved in human infections are Fusarium solani,  F.
oxysporum, F. verticilloides, and F. moniliforme [1]. Of note,
Fusarium species are often confused with Aspergillus spp. as
both pathogens have similar histopathologic appearance
with septate, dichotomously branching hyphae. Yet, the
prognosis of invasive fusariosis is much poorer than for
invasive aspergillosis, with very low response rates and
most patients with disseminated Fusarium infection dying
[1]. We describe here the first case of a favorable response
of disseminated fusariosis to combination caspofungin
and liposomal amphotericin B followed by oral suppres-
sive therapy with voriconazole in a pediatric patient with
acute lymphoblastic leukaemia (ALL).
Case presentation
A 11-year-old, 50-kg female with a diagnosis of CD10+
ALL was admitted to the hospital with fever and intermit-
tent chest pain. The patient was in complete remission
(CR) following SHOP-99 chemotherapy. At the time of
hospital admission, she was receiving G-CSF for severe
granulocytopenia post-intensification with cytarabine,
and had also received broad-spectrum antibiotics and flu-
conazole prophylaxis during previous episodes of febrile
neutropenia.
The physical examination was normal and the patient's
general condition good. The blood examination showed
12,500 leukocytes/mm3  (82% neutrophils). An urine
examination, a chest X-ray, and an abdominal ultrasonog-
raphy did not reveal abnormal findings. Blood, urine, and
stool cultures were also negative. She was initially treated
with cefepime and teicoplanin. G-CSF was discontinued,
after which the neutrophil count stabilized at around
1,700/mm3. CRP increased steadily up to 5.6 mg/dL
despite broad-spectrum antibiotic therapy. One week
later, while continuously febrile, the patient experienced
worsening chest pain. A chest CT scan revealed several
nodules 1 cm or smaller in diameter at the apex of both
lungs (Figure 1). The Aspergillus galactomannan antigen
was negative. Cultures of separate blood samples
obtained percutaneously and from the central venous
catheter, yielded Fusarium spp. The species of the infecting
Fusarium could not be identified and in vitro susceptibility
could not be tested. Liposomal amphotericin B (3 mg/kg/
day) was then started. Although the dose of liposomal
amphotericin B was increased to 5 mg/kg daily and the
central venous catheter was removed (cultures of the cath-
eter tip were sterile), the patient remained febrile and
chest pain continued to worsen over the following 7 days.
Blood cultures remained positive for Fusarium spp. and
CRP levels increased up to 10.6 mg/dL (Figure 1). Caspo-
fungin was then initiated (70-mg load followed by 50 mg
daily). Fever disappeared within 48 hours of caspofungin
onset (Figure 1). Chest pain improved significantly, blood
cultures became negative, and CRP levels went down to
the 1–2 mg/dL range over the following days. The patient
presented two isolated fever spikes 8 and 12 days after the
onset of caspofungin, which corresponded to a phlebitis
episode and a limited reaction to L-asparaginase, respec-
tively. Two weeks later, a new chest CT scan demonstrated
progressive resolution of the lung nodules (Figure 1).
Intravenous antifungals were discontinued and chemo-
therapy and suppressive therapy with oral voriconazole
200 mg twice daily was started. Three months later, a chest
CT scan showed complete resolution of the pulmonary
lesions, while the patient was asymptomatic (Figure 1).
Thus, voriconazole was discontinued. Twenty-five
months after discontinuation of all antifungal therapy,
the patient remains healthy in the absence of any symp-
toms of fungal infection and in CR of her neoplastic dis-
ease.
Fusarium  resistance to most antifungals and the severe
immunosuppression-notably long-lasting, severe neutro-
penia – in oncohematological patients make Fusarium
infections commonly fatal [1]. Despite its low activity
against Fusarium [2], amphotericin B remains the drug of
choice. Voriconazole is licensed for the treatment of fusa-
riosis based on in vitro data and a series of case reports
with a reported response rate of ~40% [3]. Posaconazole
also has potential for therapy of systemic fusariosis [4]. In
any case, responses obtained with monotherapies remain
too low and unsatisfactory.
We decided to treat our patient with amphotericin B and
caspofungin for two reasons: (i) In our view amphotericin
B remains the mainstay of therapy for fusariosis in pediat-
ric patients; experience with voriconazole in this patient
segment is limited [5-7]; (ii) Concurrent antifungal ther-
apy is now generally considered an alternative way of
improving outcome in difficult-to-treat invasive mycoses.
In a recent in vitro study amphotericin B and voriconazole
rendered mainly additive or subadditive interactions
against Fusarium spp. [8]. Yet, the concern remains that
combining amphotericin B and azoles may lead to antag-
onism. In addition to the azole inhibition of the synthesis
of amphotericin B's pharmacological target ergosterol,
amphotericin B-related damage to the fungal cell mem-
brane may interfere with the influx of azoles [9]. In vitro
caspofungin-inactive against Fusarium-showed synergistic
or synergistic-to-additive interactions with amphotericin
B for at least half of the Fusarium isolates [10]. By inhibit-
ing cell wall synthesis, caspofungin may presumably
enhance the penetration of amphotericin B [9].
We hypothesize that combination antifungal therapy
likely contributed to the sucessful treatment of our
patient's severe invasive fusariosis, since clinical improve-
ment only became evident after initiating caspofungin.BMC Infectious Diseases 2007, 7:40 http://www.biomedcentral.com/1471-2334/7/40
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Clinical, bio logical, and radiographic evolution and drug therapy Figure 1
Clinical, bio logical, and radiographic evolution and drug therapy.
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Yet, the effect of caspofungin in the successful outcome of
our case is not completely clear. The clinical response
observed could also be the result of prolonged adminis-
tration of liposomal amphotericin B and the lack of severe
neutropenia. Finally, the administration of suppressive
voriconazole and the early re-initiation of chemotherapy
allowed by rapid infection control probably also contrib-
uted to the good long-term outcome. Of note, there have
been a few case reports of response to caspofungin in
combination with amphotericin B [11,12] and as mono-
therapy [13], although in some of these reports there was
a clear association of response to recovery from neutrope-
nia.
Conclusion
We herein report an episode of disseminated fusariosis in
a pediatric ALL patient treated successfully with caspofun-
gin and amphotericin B followed by suppressive therapy
with voriconazole. While our anecdotal observation is
encouraging, the use of combination antifungal therapy is
debatable and further in vivo studies are warranted to
establish its true role in deep-seated and disseminated
Fusarium infections.
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